Edition:
United States

Erytech Pharma SA (ERYP.PA)

ERYP.PA on Paris Stock Exchange

9.11EUR
17 Aug 2018
Change (% chg)

€0.26 (+2.94%)
Prev Close
€8.85
Open
€8.80
Day's High
€9.13
Day's Low
€8.80
Volume
39,940
Avg. Vol
40,364
52-wk High
€29.70
52-wk Low
€8.61

Chart for

About

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The... (more)

Overall

Beta: 1.15
Market Cap(Mil.): €163.41
Shares Outstanding(Mil.): 17.94
Dividend: --
Yield (%): --

Financials

  ERYP.PA Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -2.94 -- --
ROI: -30.17 2.89 12.63
ROE: -30.90 1.65 14.82

BRIEF-Erytech To Present Results From Phase I Trial Of Eryaspase In All And New Pre Clinical Data At Aacr 2018

* ERYTECH TO PRESENT RESULTS FROM PHASE I TRIAL OF ERYASPASE IN ALL AND NEW PRE-CLINICAL DATA AT AACR 2018 Source text for Eikon: Further company coverage:

Apr 12 2018

BRIEF-Oncodesign Concludes A Partnership With Erytech In Oncology

* ONCODESIGN CONCLUDES A LONG TERM SERVICE-BASED PARTNERSHIP WITH ERYTECH IN ONCOLOGY

Mar 27 2018

BRIEF-Erytech FY Net Loss Widens To 33.5 Million Euros

* REPORTED ON MONDAY FY NET LOSS 33.5 MILLION EUROS, COMPARED TO 21.9 MILLION EUROS IN 2016

Mar 13 2018

Earnings vs. Estimates